Overview

Variable Interval Versus Set Interval Aflibercept for DME

Status:
Completed
Trial end date:
2018-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression. There will be approximately 50 men and women at least 18 years of age, diagnosed with type 1 or type 2 diabetes, taking part in this study at 5 locations in the United States.
Phase:
Phase 4
Details
Lead Sponsor:
California Retina Consultants
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept